Matthew Benskey, ’08, is pursuing research on the molecular neurobiology of disease — specifically, how viral vector-based genetic manipulations can halt the pathology associated with Parkinson's Disease.
Nick Kanaan, ’01, is an assistant professor of translational science and molecular medicine at Michigan State University. Studies in his Kanaan lab focus on the molecular mechanisms underlying degenerative diseases such as Alzheimer’s and Parkinson’s, the role of aging-related changes, and therapeutic strategies.
Michelle Mazei-Robison, ’99, is an assistant professor in the physiology department at Michigan State University. Her Mazei-Robison lab focuses on the molecular mechanisms that underlie changes in VTA DA neuron signaling, morphology and activity induced in neuropsychiatric disorders such as depression and addiction.
Kristi Haik, ’94, is the chair of the biological sciences department at Northern Kentucky University. She is researching development and treatment for neurodegenerative diseases such as Parkinson's and the use of nanotechnology in drug delivery to the brain.
Scott Janis, ’91, is the program director in the Office for Clinical Research at the National Institutes of Health, conducting research and overseeing two clinical trial networks in the treatment of strokes.
Deb Shear, ’98, is the section chief for the in vivo Neuroprotection Labs, Brain Trauma Neuroprotection and Neurorestoration Branch; Center of Excellence for Psychiatry and Neuroscience at the Walter Reed Army Institute of Research in Silver Spring, Maryland. Her research focuses on the exploration of neuroprotective and neurorestorative strategies for treating traumatic brain injury, including the use of neural stem cells.